Sky Labs' CART Monitor Validates BP Tracking for AF and Heart Failure Patients
Event summary
- Sky Labs presented clinical data at ESC Congress 2026 demonstrating CART's utility in monitoring BP for AF and heart failure patients.
- CART achieved an 80% analyzable data rate in AF patients and met ESH error margin criteria in heart failure patients.
- The device is prescribed in over 2,000 Korean medical institutions with 300,000 cumulative prescriptions.
- CART was recommended in the 2026 Korean Society of Hypertension Guidelines, a first for ring-type cuffless monitors.
The big picture
Sky Labs' CART monitor is positioning itself as a leader in cuffless blood pressure monitoring, particularly for complex cardiovascular conditions like AF and heart failure. The device's clinical validation and inclusion in Korean hypertension guidelines signal a potential shift in how chronic cardiovascular diseases are managed. With over 300,000 prescriptions and expanding into global markets, Sky Labs is poised to disrupt traditional BP monitoring methods.
What we're watching
- Market Expansion
- Whether Sky Labs can sustain its growth momentum in the European and global markets following its clinical validations.
- Regulatory Compliance
- The pace at which CART gains regulatory approvals in other major markets beyond Korea.
- Competitive Positioning
- How Sky Labs differentiates itself from global big tech companies in the cuffless blood pressure monitoring space.
Related topics